VJHemOnc Podcast

Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater understanding of the disease and treatment approaches, there can be better outcomes for patients. In this podcast, Carolina Vincente-Duenas from the Institute of Biomedical Research, Salamanca, Spain, Talha Badar of the Medical College of Wisconsin, Milwaukee, WI, and Christina Peters of St. Anna Children’s Hospital, Vienna, Austria, discuss key updates in ALL presented at this year’s virtual European Hematology Association (EHA) 2020 congress.

The post Key updates in ALL at EHA 2020 appeared first on VJHemOnc.

The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R) disease, and transplant-eligible patients. The impact of measurable residual disease (MRD) negativity in the clinical decision-making process for patients with multiple myeloma remains a hotly debated topic among the experts.

In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, chairs a discussion with Francesca Gay, MD, PhD, University of Turin, Turin, Italy, and Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, on the most important updates and latest research evidence in multiple myeloma.

The post The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients appeared first on VJHemOnc.

Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with an associated hematological neoplasm (SM-AHN) or mast cell leukemia.

In this insightful podcast, Deepti Radia, MBBS, MRCPI, FRCPath, of Guy’s and St Thomas’ Hospital NHS Foundation Trust, London UK, firstly discusses the management of patients with systemic mastocytosis with associated hematological neoplasm. Dr Radia also details the current treatment options for this condition, as well as on-going clinical trials. Additionally, Dr Radia discusses the management of hematological oncology patients during the COVID-19 pandemic.

The post Systemic mastocytosis: current landscape, novel agents and COVID-19 appeared first on VJHemOnc.

Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable residual disease (MRD) assessment has improved prognostic precision, providing a strong rationale for it’s use to guide treatment, and compare therapy efficacy. MRD can be evaluated using an array of multiparameter flow cytometry and molecular approaches. However, these methods have not been standardized, making their utilization in clinical practice challenging.

The post MRD assessment in AML: incorporation into clinical practice appeared first on VJHemOnc.

The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians is a very real concern. Typically presenting with reduced immunity to viral infection, patients with multiple myeloma are at greater risk of COVID-19.

In this podcast, Prof. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the adversities being faced due to the coronavirus pandemic, risk factors, and how negative outcomes can be minimized. Specifically, Prof. Mohty discusses the ways hospital visits can be reduced and treatments amended to reduce risk while still maintaining efficacy.

The post Myeloma management in the COVID-19 era appeared first on VJHemOnc.